Advanced bladder cancers respond to immunotherapy regardless of gene mutation status eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Published 16 February 2021
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Angela Smith discussing deintensification of management of low-risk non-muscle-invasive bladder cancer. Dr. Smith notes that it is important to distinguish between low risk versus low grade non-muscle-invasive bladder cancer. According to the AUA risk stratification for non-muscle-invasive bladder cancer low risk disease is either a low-grade solitary Ta 3 cm tumor or PUNLMP. Conversely, there are several instances where low grade tumors are intermediate risk, including low grade Ta tumors that recur within 1 year of resection, solitary low grade Ta tumors 3cm, and multifocal low grade Ta tumors.